Skip to main content
SpringerLink
Log in

Advances in Ovarian Cancer and Ongoing Clinical Trials

  • Chapter
  • First Online:
Gynecological Cancers

Part of the book series: Current Clinical Oncology ((CCO))

  • 800 Accesses

Abstract

Bevacizumab, a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF), has gained European Medicine Agency approval for the frontline treatment of advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in combination with carboplatin and paclitaxel, and for the treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and gemcitabine. The addition of bevacizumab to standard chemotherapy as frontline treatment (GOG-0218 and ICON7) or in recurrent disease (OCEANS and AURELIA) shows significant efficiency. Promising data have been published for a number of emerging antiangiogenic agents.

Currently, single agent trabectedin is approved for treatment of patients with advanced soft tissue sarcoma after failure of anthracyclines and ifosfamide, and in association with pegylated liposomal doxorubicin for treatment of patients with relapsed partially platinum-sensitive ovarian cancer. In particular, its peculiar mechanisms of action suggest its potential activity in specific subsets of ovarian cancer patients endowed with BRCA mutation or the so-called BRCAness phenotype (i.e., serous, high-grade carcinomas; repeated response to platinum-based regimens); this is likely to enlarge in the future the clinical settings in which candidates can take advantage of even single agent trabectedin.

PARP inhibitors are proteins involved in the base excision repair of DNA single-strand breaks and represent one of the most promising targeted therapy demonstrating single-agent activity in BRCA-related and sporadic high grade serous ovarian cancer. Active search is ongoing in order to define biomarkers predictive of response to these novel treatments, and also to help clarify the biological mechanisms sustaining the achievement of long-lasting stable disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Jayson GC, Kohn EC, Kitchener H, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.

    Article  PubMed  Google Scholar 

  3. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2014;14(10):1020–6.

    Article  Google Scholar 

  4. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396–405.

    Article  CAS  PubMed  Google Scholar 

  5. Chan J, Brady M, Penson R, Monk B, Boente M, Walker J, et al. Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/− bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712) (Oral presentation). 18th international meeting of the European Society of Gynecological Oncology; 19–22 Oct 2013; Liverpool.

    Google Scholar 

  6. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in Ovarian Cancer, 2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#ovarian. Accessed 28 Nov 2014.

  7. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2012;363:943–53.

    Article  Google Scholar 

  8. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v23–30.

    Article  PubMed  Google Scholar 

  9. Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, et al. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. Obstet Gynecol. 2012;2012:245756.

    Google Scholar 

  10. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.

    Article  CAS  PubMed  Google Scholar 

  11. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.

    Article  CAS  PubMed  Google Scholar 

  12. Oza AM, Perren TJ, Swart AM, Schroder W, Pujade- Lauraine E, Havsteen H, et al. ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer [abstract]. Eur J Cancer. 2013;49(2):6.

    Google Scholar 

  13. Aghajanian C, Blank SV, Goff BA, Judson P, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without Bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S, et al. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol. 2014;133(1):105–10.

    Article  CAS  PubMed  Google Scholar 

  15. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–8.

    Article  CAS  PubMed  Google Scholar 

  16. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube and peritoneal cancer. J Clin Oncol. 2009;27:5601–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ledermann J, Perren TJ, Raja FA, Embleton A, Rustin G, Jayson GC et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial [abstract]. 13th Annual European cancer congress; 27 Sept to 1 Oct 2013; Amsterdam.

    Google Scholar 

  18. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799–808.

    Article  CAS  PubMed  Google Scholar 

  19. Ledermann J, Perren TJ, Raja FA, Embleton A, Rustin G, Jayson GC, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial [abstract]. Eur J Cancer. 2013;49(2):10.

    Google Scholar 

  20. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107–14.

    Article  CAS  PubMed  Google Scholar 

  21. European Medicines Agency (EMA). Assessment Report for Yondelis. International non-proprietary name/common name; Trabectedin procedure. No EMEA/H/C/000773/11/0008. 2009. http://www.ema.europa.eu/humandocs/PDFs/EPAR/Yondelis/EMEA-H-773-II-08-AR.pdf.

  22. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics. 2010;11(6):865–78.

    Article  CAS  PubMed  Google Scholar 

  23. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 2005;65(7):2964–71.

    Article  CAS  PubMed  Google Scholar 

  24. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45(12):2116–22.

    Article  CAS  PubMed  Google Scholar 

  25. Von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008;19(10):1802–9.

    Article  Google Scholar 

  26. Del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol. 2013;30(1):435.

    Article  PubMed  Google Scholar 

  27. Ferrandina G, Salutari V, Vincenzi B, Marinaccio M, Naglieri E, Loizzi V, et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study. Gynecol Oncol. 2013;130(3):505–10.

    Article  CAS  PubMed  Google Scholar 

  28. Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22(1):39–48.

    Article  CAS  PubMed  Google Scholar 

  29. Fisher M, Gore M. Cost-effectiveness of trabectedin plus pegylated liposomal doxorubicin for the treatment of women with relapsed platinum-sensitive ovarian cancer in the UK: analysis based on the final survival data of the OVA-301 trial. Value Health. 2013;16(4):507–16.

    Article  PubMed  Google Scholar 

  30. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.

    Article  CAS  PubMed  Google Scholar 

  31. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382–92.

    Article  CAS  PubMed  Google Scholar 

  32. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.

    Article  CAS  PubMed  Google Scholar 

  33. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30(4):372–9.

    Article  CAS  PubMed  Google Scholar 

  34. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.

    Article  CAS  PubMed  Google Scholar 

  35. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882–92.

    Article  CAS  PubMed  Google Scholar 

  36. Mirza MR, Monk BJ, Ledermann JA, Oza AM, Del Campo JM, Berek JS, et al. Engot-OV16/NOVA: a phase 3 randomized double-blind trial of maintenance with PARP inhibitor Niraparib versus placebo in patients with platinum-sensitive ovarian cancer. Int J Gynecol Cancer. 2014;24(9):33–4.

    Google Scholar 

  37. Coleman RL, Sill M, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation [abstract]. 45th Annual meeting on women’s cancer (SGO); 22–25 Mar 2014; Tampa, FL.

    Google Scholar 

  38. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2:1048–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036–47.

    Article  CAS  PubMed  Google Scholar 

  40. Farley J, Brady WE, Mirrer BJ, Lankes H, Coleman R, et al. A phase II trial of Selumetinib (AZD6244; ARRY-142886) in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. American Association for Cancer Research annual meeting, 31 Mar to 4 Apr 2012; Chicago, IL.

    Google Scholar 

  41. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14:134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Monk BJ, Grisham RN, Marth C, Banerjee SN, Hilpert F, Coleman RL, et al. The MEK inhibitor in low-grade serous ovarian cancer (MILO)/ENGOT-ov11 study: a multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2014;32:5.

    Article  Google Scholar 

  43. McCormack PL. Nintedanib: first global approval. Drugs. 2015;75(1):129–39.

    Article  CAS  PubMed  Google Scholar 

  44. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–82.

    Article  CAS  PubMed  Google Scholar 

  45. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798–804.

    Article  CAS  PubMed  Google Scholar 

  46. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-20-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110:1923–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012;18(19):5399–411.

    Article  CAS  PubMed  Google Scholar 

  48. Poveda A, Berton-Rigaud D, Ray-Coquard IL, Kong B, Provansal M, Soto A, et al. Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study. J Clin Oncol. 2014;32:5s. Abstract no. 5505.

    Article  Google Scholar 

  49. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Okazaki T, Tanaka y Y, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS- 936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2014;32:5s. Abstract no. 5511.

    Article  Google Scholar 

  51. Armstrong DK, White AJ, Weil SC, Philips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 2013;129(3):452–8.

    Article  CAS  PubMed  Google Scholar 

  52. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;11:1207–14.

    Article  Google Scholar 

  53. Matulonis U, Wulf GM, Birrer MJ, Westin SN, Torres-Lockhart K, Prat A, et al. Phase I of oral BKM120 and oral olaparib for high grade serous ovarian cancer or triple negative breast cancer. J Clin Oncol. 2014;32:5. Abstract no. 2510.

    Article  Google Scholar 

  54. Hodi FS, Butler M, Oble DA, Seiden MV, Quy P, Bell-McGuinn KM, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Chelius D, Ruf P, Gruber P, Plöscher M, Haluska FG, Kruse A, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs. 2010;2:309–19.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Berek JS, Edwards RP, Parker L, De Mars LR, Herzog TJ, Lentz SS, et al. Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. J Clin Oncol. 2011;29:5048.

    Google Scholar 

  57. Pietzner K, Chekerov R, Reinthaller A, Reimer D, Reimer T, Angleitner-Boubenizek L, et al. A matched pair analysis of intra- and postoperative catumaxomab in patients with ovarian cancer from a multicenter, single- arm phase II trial versus a consecutive single-center collective of ovarian cancer patients without immunotherapy. J Clin Oncol. 2012;30:5080.

    Google Scholar 

  58. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.

    Article  Google Scholar 

  59. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16:389.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol. 2005;23(9):1867–74.

    Article  CAS  PubMed  Google Scholar 

  61. Krasner CN, McMeekin DS, Chan S, et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer. 2007;97(12):1618–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Del Campo JM, Roszak A, Bidzinski M, et al. Yondelis Ovarian Cancer Group. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol. 2009;20(11):1794–802.

    Article  PubMed  Google Scholar 

  63. Lorusso D, Scambia G, Pignata L, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol. 2015;17 [Epub ahead of print].

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Agostino Gemelli Hospital, Catholic University of Sacred Heart, Largo Agostino Gemelli, 8, Rome, 00168, Italy

    Valeria Masciullo MD, PhD, Cristina Di Cesare MD & Ida Paris MD

Authors
  1. Valeria Masciullo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina Di Cesare MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ida Paris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valeria Masciullo MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Biology, Temple University, Philadelphia, Pennsylvania, USA

    Antonio Giordano

  2. Department of Biology, Temple University, Philadelphia, Pennsylvania, USA

    Marcella Macaluso

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Masciullo, V., Di Cesare, C., Paris, I. (2016). Advances in Ovarian Cancer and Ongoing Clinical Trials. In: Giordano, A., Macaluso, M. (eds) Gynecological Cancers. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-32907-9_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32907-9_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32905-5

  • Online ISBN: 978-3-319-32907-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation